<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1131">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392468</url>
  </required_header>
  <id_info>
    <org_study_id>1289.27</org_study_id>
    <nct_id>NCT02392468</nct_id>
  </id_info>
  <brief_title>Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers</brief_title>
  <official_title>Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate&#xD;
      the ocular and systemic safety and pharmacokinetics during 14 day treatment period in&#xD;
      patients with schizophrenia, Alzheimer's disease, or age comparable healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2015</start_date>
  <completion_date type="Actual">August 10, 2017</completion_date>
  <primary_completion_date type="Actual">August 10, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of subjects with Adverse Events (AE), coded to the Medical Dictionary for Regulatory Activities, System Organ Class Eye disorders, as determined by the investigator at End of Study</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with drug-related AEs as determined by the investigator at End of Study</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss - maximum measured concentration of the analyte in plasma at steady-state</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss - time from dosing to maximum measured concentration of the analyte in plasma at steady-state.</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>BI 409306 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose of BI 409306</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose of BI 409306</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306 matching placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>BI 409306 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306 matching placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>BI 409306 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>low dose</description>
    <arm_group_label>BI 409306 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>high dose</description>
    <arm_group_label>BI 409306 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Schizophrenia group:&#xD;
&#xD;
               -  Patients with established diagnoses of schizophrenia (per Diagnostic and&#xD;
                  Statistic Manual of Mental Disorder, version V) with the all of the following&#xD;
                  clinical features:&#xD;
&#xD;
                    -  Clinically stable and are in the residual (non-acute) phase of their illness&#xD;
                       for at least 8 weeks prior to randomisation&#xD;
&#xD;
                    -  Current antipsychotic and concomitant psychotropic medications must meet the&#xD;
                       criteria below:&#xD;
&#xD;
                         -  Maintained on current atypical (second generation) antipsychotic&#xD;
                            medications (in any approved dosage form) other than Clozapine and on&#xD;
                            current dose for at least 8 weeks prior to randomisation, and/or&#xD;
&#xD;
                         -  Maintained on current typical (first generation) antipsychotic&#xD;
                            medications and on current dose for at least 6 months, optionally&#xD;
                            combined with anticholinergics if treated with a stable dose for at&#xD;
                            least 6 months prior to randomisation, and/or&#xD;
&#xD;
                         -  Maintained on current concomitant psychotropic medications other than&#xD;
                            anticholinergics, antiepileptics and lithium, and on current dose for&#xD;
                            at least 8 weeks prior to randomisation. Antiepileptics and lithium are&#xD;
                            allowed if initiated at least 6 months prior to randomisation.&#xD;
&#xD;
                    -  Have no more than a moderate severity rating on hallucinations and delusions&#xD;
                       (Positive and Negative Syndrome Scale (PANSS), positive syndrome&#xD;
                       Hallucinatory Behavior item score &lt;= 4 and Delusions item score &lt;= 4)&#xD;
&#xD;
                    -  Have no more than a moderate severity rating on positive formal thought&#xD;
                       disorder (PANSS, positive syndrome Conceptual Disorganization item score &lt;=&#xD;
                       4)&#xD;
&#xD;
                    -  Have a minimal level of extrapyramidal symptoms (Simpson-Angus Scale total&#xD;
                       score &lt; 6) and depressive symptoms (PANSS, general psychopathology syndrome&#xD;
                       Depression item score &lt;= 4)&#xD;
&#xD;
               -  Male or female patients age 18 to 55 years.&#xD;
&#xD;
          -  Alzheimer's Disease group:&#xD;
&#xD;
               -  Patients with diagnosis of mild Alzheimer's Dementia based on DSM-V and in&#xD;
                  accordance with the recommendations from the National Institute on&#xD;
                  Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's&#xD;
                  disease.&#xD;
&#xD;
               -  Mini-Mental State Examination (MMSE) score of 18-26.&#xD;
&#xD;
               -  Male or female patients age 55 to 85 years, who have not been taking acetyl&#xD;
                  cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and/or memantine&#xD;
                  for at least 3 months or on stable dose of acetyl cholinesterase inhibitors&#xD;
                  (donepezil, galantamine, rivastigmine) and/or memantine at least 3 months before&#xD;
                  randomization.Patients older than 85 years may be included based on an acceptable&#xD;
                  general health status, (e.g. concomitant diseases, physical capability to follow&#xD;
                  the required study procedures [visits etc.]) per investigators judgement.&#xD;
&#xD;
               -  Availability of a pre-existing cranial computer tomography (CCT) or magnetic&#xD;
                  resonance imaging (MRI) scan of the brain (initiation of radiological imaging is&#xD;
                  not required) not older than one year prior to screening; if not available, a CCT&#xD;
                  must be performed at screening. Results of radiological brain imaging must be&#xD;
                  compatible with Diagnosis of Alzheimer's Disease and exclusion of relevant signs&#xD;
                  indicative of potential vascular dementia (see also exclusion criteria).&#xD;
&#xD;
               -  If needed, a caregiver may be present during site activities.&#xD;
&#xD;
          -  Age-comparable male or female healthy volunteers age 18 to 85 years. Healthy&#xD;
             volunteers older than 85 years may be included based on an acceptable general health&#xD;
             status, (e.g. concomitant diseases, physical capability to follow the required study&#xD;
             procedures [visits etc.]) per investigators judgement:&#xD;
&#xD;
               -  After 10 patients with schizophrenia (as described above) are entered into the&#xD;
                  study, the median age of the group will be computed. Five healthy volunteers at&#xD;
                  or below the median age but greater than 18 years old and five healthy volunteers&#xD;
                  above the median but less than 55 will be entered into the study.&#xD;
&#xD;
               -  Similarly, after 10 patients with AD are entered, the median age will be&#xD;
                  computed. Five healthy volunteers at or below the median age but greater than 55&#xD;
                  years old and five healthy volunteers above the median but less than 85 will be&#xD;
                  entered into the study.&#xD;
&#xD;
          -  Subjects must exhibit reliability and physiologic capability to comply with all&#xD;
             protocol procedures.&#xD;
&#xD;
          -  Signed and dated written informed consent by date of Visit 1 in accordance with Good&#xD;
             Clinical Practice and the local legislation. If the patient needs a legal&#xD;
             representative, then this legal representative must give written informed consent as&#xD;
             well.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Presence of active ocular conditions with or without visual impairment due to any&#xD;
             causes (e.g. cataract, chorioretinal macular lesion, amblyopia, active diabetic&#xD;
             retinopathy, uncontrolled glaucoma, active inflammation or infection, etc.) in one eye&#xD;
             or both eyes at the screening phase.&#xD;
&#xD;
          -  Planned ocular treatment (e.g. intravitreal antivascular growth factor,&#xD;
             corticosteroids) or surgery during the study period.&#xD;
&#xD;
          -  Current or planned use of ocular or systemic corticosteroids.&#xD;
&#xD;
          -  Current or planned use of medications known to be toxic to the retina, lens, optic&#xD;
             nerve&#xD;
&#xD;
          -  Subjects treated with more than two antipsychotic medications (including more than two&#xD;
             dosage forms).&#xD;
&#xD;
          -  Dementia in Alzheimers Disease patients, secondary to other disorders (based on&#xD;
             clinical data and/or current laboratory findings and/or on a pre-existing cranial MRI&#xD;
             or CCT).&#xD;
&#xD;
          -  Neurological disease (other than Dementia of Alzheimer Type such as: Lewy body&#xD;
             dementia - primary diagnosis, Huntington's disease, Parkinson's Disease encephalitis,&#xD;
             epilepsy, vascular or multi-infarct dementia, stroke, congenital mental deficiency, or&#xD;
             multiple sclerosis), or mental retardation.&#xD;
&#xD;
          -  Subjects needing to take long-acting hypnotics or anxiolytic (i.e. Diazepam).&#xD;
&#xD;
          -  For AD patients, the following drugs are prohibited for 3 months prior to&#xD;
             randomization and for the duration of the trial:&#xD;
&#xD;
               -  tricyclic antidepressants,&#xD;
&#xD;
               -  antidepressants that are monoamine oxidase inhibitors,&#xD;
&#xD;
               -  neuroleptics with moderate or greater anticholinergic potency (e.g.,&#xD;
                  chlorpromazine, fluphenazine, loxapine, perphenazine, thioridazine),&#xD;
&#xD;
               -  anticholinergic medications.&#xD;
&#xD;
               -  Intake of St. John's wort, Carbamazepine and extracts from Ginko as they are&#xD;
                  relevant CYP2C19 inducers.&#xD;
&#xD;
          -  Substantial concomitant cerebrovascular disease (defined by a history of a&#xD;
             stroke/intracranial haemorrhagia temporally related to the onset of worsening of&#xD;
             cognitive impairment).&#xD;
&#xD;
          -  Any suicidal ideation of type 4 or 5 in the Columbia Suicidal Severity Rating Scale&#xD;
             (C-SSRS) in the past 3 months.&#xD;
&#xD;
          -  Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt,&#xD;
             aborted attempt, or preparatory acts or behavior).&#xD;
&#xD;
          -  History or diagnosis of symptomatic and unstable/uncontrolled gastrointestinal,&#xD;
             hepatic, renal, respiratory, cardiovascular, metabolic, immunological, haematological&#xD;
             or hormonal disorders.&#xD;
&#xD;
          -  For female subjects:&#xD;
&#xD;
             --Pre-menopausal women (last menstruation &lt;=1 year prior to informed consent) who:&#xD;
&#xD;
               -  are nursing or pregnant or&#xD;
&#xD;
               -  are of child-bearing potential and are not practicing an acceptable method of&#xD;
                  birth control&#xD;
&#xD;
          -  For male subjects: Men who are able to father a child, unwilling to be abstinent or&#xD;
             use adequate contraception.&#xD;
&#xD;
          -  Known history, or new diagnosis of HIV infection.&#xD;
&#xD;
          -  Significant renal disease (CLCR &lt; 30 mL/min).&#xD;
&#xD;
          -  Bodyweight &lt; 50 kg.&#xD;
&#xD;
          -  Indication of liver disease.&#xD;
&#xD;
          -  History of neurologic (e.g. stroke, seizure without a clear and resolved etiology,&#xD;
             concussion accompanying loss of consciousness) or psychiatric condition.&#xD;
&#xD;
          -  History of malignancy within the last 5 years, except for basal cell carcinoma.&#xD;
&#xD;
          -  Planned elective surgery requiring general anaesthesia, or hospitalisation during the&#xD;
             study period.&#xD;
&#xD;
          -  Significant history of drug dependence&#xD;
&#xD;
          -  Clinically significant uncompensated hearing loss. Use of hearing aids is not allowed.&#xD;
&#xD;
          -  Further exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altman Clinical and Translational Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memory Enhancement Center of America, Inc.</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BI 409306</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

